Volume 8.08 | Mar 4

Immune Regulation News 8.08 March 4, 2016
Immune Regulation News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Like Us on Facebook  IRN on Twitter
Immunologists Find New Ways to Beat the ‘Bad Guys’
Researchers have uncovered the mechanism by which a promising vaccine adjuvant, chitosan, induces an immune response. The team’s discovery provides a roadmap to develop vaccines that trigger cell-mediated immunity. [Press release from Trinity College Dublin discussing online publication in Immunity]
Press Release | Video | Abstract | Graphical Abstract
Request Your Free Wallchart: Innate Lymphoid Cells
PUBLICATIONS (Ranked by impact factor of the journal)
MAP Kinase Inhibition Promotes T Cell and Anti-Tumor Activity in Combination with PD-L1 Checkpoint Blockade
The authors showed that mitogen-activated protein kinase (MAPK) kinase (MEK) inhibition did profoundly block naive CD8+ T cell priming in tumor-bearing mice, but actually increased the number of effector-phenotype antigen-specific CD8+ T cells within the tumor. MEK inhibition protected tumor-infiltrating CD8+ T cells from death driven by chronic TCR stimulation while sparing cytotoxic activity. [Immunity] Abstract

Control of T Cell Antigen Reactivity via Programmed TCR Downregulation
Investigators found that activated CD4+ T cells, at the peak of clonal expansion, persistently downregulated their T cell antigen receptor (TCR) expression in proportion to the strength of the initial antigen recognition. [Nat Immunol] Abstract

IFN-Gamma and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma
The authors report that IFN-gamma and CCL2 released systemically in response to a CD40 agonist cooperate to redirect a subset of Ly6C+CCR2+ monocytes/macrophages to infiltrate tumors and deplete fibrosis. [Cancer Discov] Abstract | Press Release

Dendritic Cell Vaccines Based on Immunogenic Cell Death Elicit Danger Signals and T Cell–Driven Rejection of High-Grade Glioma
Researchers combined dendritic cell (DC) immunotherapy with immunogenic cell death (ICD) induced by hypericin-based photodynamic therapy. In an orthotopic high-grade glioma (HGG) mouse model involving prophylactic/curative setups, both biologically and clinically relevant versions of ICD-based DC vaccines provided strong anti-HGG survival benefit. [Sci Transl Med] Abstract | Press Release

EAF2 Mediates Germinal Center B-Cell Apoptosis to Suppress Excessive Immune Responses and Prevent Autoimmunity
The authors showed that ELL-associated factor 2 (EAF2) is selectively upregulated in germinal center (GC) B cells among various immune cell types and promotes apoptosis of GC B cells both in vitro and in vivo. [Nat Commun] Full Article

Neurodegeneration Triggers Peripheral Immune Cell Recruitment into the Forebrain
Researchers identified neurodegeneration as a potent trigger for peripheral immune cell recruitment into the mouse forebrain. Subsequent immunization with myelin oligodendrocyte glycoprotein 35–55 peptide, which induces myelin autoreactive T cells in the periphery, resulted in massive immune cell recruitment into the affected forebrain. [J Neurosci] Abstract | Press Release

T Follicular Helper Expansion and Humoral-Mediated Rejection Are Independent of the HVEM/BTLA Pathway
Scientists assessed the role of the herpesvirus entry mediator/B- and T-lymphocyte attenuator (HVEM/BTLA) signaling pathway in the context of antibody-mediated allograft rejection. [Cell Mol Immunol] Abstract

CD19xCD3 DART Protein Mediates Human B-Cell Depletion In Vivo in Humanized BLT Mice
Scientists present findings of specific and systemic human B-cell depletion by a CD19xCD3 dual-affinity re-targeting (DART) protein in humanized BLT mice. Administration of the CD19xCD3 DART protein resulted in a dramatic sustained depletion of human CD19+ B cells from the peripheral blood, as well as a dramatic systemic reduction of human CD19+ B-cell levels in all tissues analyzed. [Mol Ther Oncolytics] Full Article

Don’t forget to subscribe to Human Immunology News and Immunology of Infectious Disease News!

Isolate particle-free human CD4+CD127lowCD25+ regulatory T cells (Tregs) in less than one hour. Request a sample today.
Purinergic Regulation of the Immune System
The authors review how local purinergic signaling changes over time during tissue responses to injury or disease, and discuss the potential of targeting purinergic signaling pathways for the immunotherapeutic treatment of ischemia, organ transplantation, autoimmunity or cancer. [Nat Rev Immunol] Abstract

Visit our reviews page to see a complete list of reviews in the immune regulation research field.

Join us for Advances in Immuno-oncology 2016 in London!
Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster
Advaxis, Inc. announced that data from a Phase II study of its lead Lm immunotherapy candidate in HPV-associated head and neck cancer, axalimogene filolisbac, has been selected as a late-breaker poster presentation. [Press release from Advaxis, Inc. discussing research to be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

From our sponsor: Studying ESCs or iPSCs? Request your free copy of the small molecules wallchart.
Cancer MoonShot 2020 Community Oncology Milestone: National Immunotherapy Coalition (NIC) Partners with New England Cancer Specialists to Advance Cancer Care in New England
Cancer MoonShot 2020 announced its clinical affiliation with New England Cancer Specialists, aimed to greatly expand patients’ access to advanced cancer care, innovative clinical trials, and survivorship resources in the community. [Cancer MoonShot 2020] Press Release

Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis in adults in the European Union who are candidates for systemic therapy. [Eli Lilly and Company] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Innate Immunity in Host-Pathogen Interactions
May 26-29, 2016
Heidelberg, Germany

Visit our events page to see a complete list of events in the immune regulation community.
NEW Postdoctoral Researcher – Single Cell Analysis of Human T Cell Development (Ghent University)

Senior Scientist – Immunology and Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Clinical Immunology (Benaroya Research Institute at Virginia Mason)

Postdoctoral Fellow – Antibody-Based Therapeutics (Inserm)

Postdoctoral Fellow – Autoimmune, Inflammatory and Demyelinating Diseases (Queen’s University Belfast)

Postdoctoral Positions – Innate Immunity and Autoimmunity (UT Southwestern Medical Center)

Faculty Positions – Immunology (University of Texas Health Science Center)

Senior Scientist – Immunology (Bavarian Nordic GmbH)

Assistant or Associate Professor – Immunity and Tolerance (Cincinnati Children’s Hospital Medical Center)

Postdoctoral Position – Immunology (Indiana University)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Immune Regulation News: Archives | Events | Contact Us